Immunovant, Inc.

Immunovant, Inc.verified

IMVT

Price:

$28.22

Market Cap:

$4.13B

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.[Read more]

Industry

Biotechnology

IPO Date

2019-06-21

Stock Exchange

NASDAQ

Ticker

IMVT

The PE Ratio as of July 2024 (TTM) for Immunovant, Inc. (IMVT) is -15.01

According to Immunovant, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -15.01. This represents a change of -19.61% compared to the average of -18.67 of the last 4 quarters.

Immunovant, Inc. (IMVT) Historical PE Ratio (quarterly & annually)

How has IMVT PE Ratio performed in the past?

The mean historical PE Ratio of Immunovant, Inc. over the last ten years is -10.11. The current -15.01 PE Ratio has changed 14.74% with respect to the historical average. Over the past ten years (40 quarters), IMVT's PE Ratio was at its highest in in the September 2019 quarter at 821.75. The PE Ratio was at its lowest in in the March 2019 quarter at -63569.44.

Quarterly (TTM)
Annual

Average

-10.11

Median

-9.59

Minimum

-16.83

Maximum

-3.86

Immunovant, Inc. (IMVT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Immunovant, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 134.67%

Maximum Annual PE Ratio = -3.86

Minimum Annual Increase = -70.57%

Minimum Annual PE Ratio = -16.83

Quarterly (TTM)
Annual
YearPE RatioChange
2024-16.8386.03%
2023-9.05134.67%
2022-3.86-70.57%
2021-13.1029.32%
2020-10.1331.35%

Immunovant, Inc. (IMVT) Average PE Ratio

How has IMVT PE Ratio performed in the past?

The current PE Ratio of Immunovant, Inc. (IMVT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-9.91

5-year avg

-10.59

10-year avg

-10.11

Immunovant, Inc. (IMVT) PE Ratio vs. Peers

How is IMVT’s PE Ratio compared to its peers?

Immunovant, Inc.’s PE Ratio is less than Arbutus Biopharma Corporation (-9.23), less than Arcutis Biotherapeutics, Inc. (-5.10), greater than Legend Biotech Corporation (-23.34), less than Protagonist Therapeutics, Inc. (15.75), less than IVERIC bio, Inc. (0), greater than Akero Therapeutics, Inc. (-33.43), less than Madrigal Pharmaceuticals, Inc. (-9.00), less than Apellis Pharmaceuticals, Inc. (-12.88), less than 89bio, Inc. (-11.15), less than Pliant Therapeutics, Inc. (-5.29), less than Arcellx, Inc. (-4.59), greater than Stoke Therapeutics, Inc. (-66.28), less than Blueprint Medicines Corporation (-6.18), greater than Amylyx Pharmaceuticals, Inc. (-25.00), less than Karuna Therapeutics, Inc. (-1.86), greater than Day One Biopharmaceuticals, Inc. (-29.52), less than null (-6.50),

Build a custom stock screener for Immunovant, Inc. (IMVT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunovant, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunovant, Inc. (IMVT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunovant, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Immunovant, Inc.'s PE Ratio?

How is the PE Ratio calculated for Immunovant, Inc. (IMVT)?

What is the highest PE Ratio for Immunovant, Inc. (IMVT)?

What is the 3-year average PE Ratio for Immunovant, Inc. (IMVT)?

What is the 5-year average PE Ratio for Immunovant, Inc. (IMVT)?

How does the current PE Ratio for Immunovant, Inc. (IMVT) compare to its historical average?